Premium
Findings in electrooculography and multifocal electroretinography in patients after bevacizumab treatment for age‐related macular degeneration
Author(s) -
MANKOWSKI W
Publication year - 2009
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2009.3321.x
Subject(s) - medicine , ophthalmology , bevacizumab , electrooculography , electroretinography , visual acuity , macular degeneration , erg , electrophysiology , eye movement , surgery , retinal , chemotherapy
Purpose To assess usefulness of electrooculography (EOG) and multifocal electroretinography (mfERG) in monitoring electrophysiological changes in patients after bevacizumab treatment. Methods 33 patients with age‐related macular degeneration underwent ophthalmic examination including visual acuity, EOG, mfERG (Vision Monitor, Metrovision, France). Visual acuity test, sensory EOG protocol and mfERG with 61 scaled hexagons for low vision protocol were used during electrophysiological exams before and 1 month after each bevacizumab injection. Results before bevacizumab injection mean visual acuity was 0,181±0,160, mean Arden’s coefficient was 199,692±54,785%, mean P1 wave amplitude <2 deg was 29,062±14,89 nV/deg2, mean P1 wave <2 deg implicit time was 47,015±12,832 ms. 1 month afer bevacizumab injection we observed no statistically significant mean visual acuity decrease (0,181±0,160 vs. 0,162±0,140 p=0,757), no statistically significant mean P1 wave amplitude <2 deg decrease (29,062±14,89 vs 25,077±17,996 nV/deg2 p=0,544) and no statistically significant mean P1 wave <2 deg implicit time decrease (47,015±12,832 vs. 46,115±10,313 ms p=0,845). We observed positive correlation between visual aciuty and P1 wave amplitude <2 deg (r=0,540, p<0,05). Conclusion Electrooculography and multifocal electroretinography are useful exams in monitoring electrophysiological changes in patients during bevacizumab treatment.